{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:11Z","timestamp":1788797831825,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.amjcard.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T06:12:06Z","timestamp":1550815926000},"page":"1602-1609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy"],"prefix":"10.1016","volume":"123","author":[{"given":"Nicole","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oth","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hartsfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.02.014_bib0001","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0002","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-157-10-201211200-00011","volume":"157","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0003","article-title":"Beta-blockers for hypertension","volume":"11","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0004","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jcin.2016.05.048","article-title":"Predictors, trends, and outcomes (among older patients \u226565 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: Insights from the NCDR registry","volume":"9","author":"Motivala","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0005","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0006","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.jacc.2017.02.001","volume":"69","author":"Patel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamainternmed.2013.12855","article-title":"Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials","volume":"174","author":"Stergiopoulos","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0008","first-page":"S347","article-title":"A systematic review of the economic burden of chronic angina","volume":"10","author":"Reynolds","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0009","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.amjcard.2015.08.002","article-title":"Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions","volume":"116","author":"Page","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40256-013-0038-z","article-title":"Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris","volume":"13","author":"Ling","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0011","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.clinthera.2012.04.025","article-title":"Costs and clinical outcomes associated with use of ranolazine for treatment of angina","volume":"34","author":"Phelps","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0012","unstructured":"Consumer Price Index details report tables annual average 2016. https:\/\/www.bls.gov\/cpi\/tables.htm. Accessed 22 June 2018."},{"key":"10.1016\/j.amjcard.2019.02.014_bib0013","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial","volume":"391","author":"Al-Lamee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(17)32757-5","article-title":"Last nail in the coffin for PCI in stable angina","volume":"391","author":"Brown","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0016","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ahj.2013.11.001","article-title":"Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: evidence from the NCDR","volume":"167","author":"Lichtman","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/CEOR.S89331","article-title":"Patient-level costs of major cardiovascular conditions: a review of the international literature","volume":"8","author":"Nicholson","year":"2016","journal-title":"ClinicoEconomics and Outcomes Res"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCOUTCOMES.113.000139","article-title":"Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial","volume":"6","author":"Spertus","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3949\/ccjm.85gr.17004","article-title":"PCI for stable angina: a missed opportunity for shared decision-making","volume":"85","author":"Rothberg","year":"2018","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjcard.2019.02.014_bib0021","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.amjcard.2018.08.027","article-title":"Clinical and economic outcomes of ranolazine versus conventional antianginals users among veterans with chronic stable angina pectoris","volume":"122","author":"Bress","year":"2018","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491930219X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491930219X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:29:16Z","timestamp":1757572156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291491930219X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S000291491930219X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.014","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}